Plasma Proteoforms Reflecting Hematopoietic Stress

Abstract

Hematopoietic stress represents a dynamic state in which the bone marrow and peripheral blood system respond to infection, inflammation, blood loss, hypoxia, nutritional deficiency, cytotoxic exposure, malignancy, or chronic systemic disease. Conventional laboratory tests, including complete blood counts, reticulocyte measurements, and differential leukocyte analysis, describe cellular consequences but may not fully capture the molecular processes that precede or accompany these changes. Plasma proteoform profiling expands the diagnostic perspective by characterizing distinct molecular forms of proteins generated through alternative splicing, proteolytic processing, oxidation, phosphorylation, glycosylation, acetylation, and other post-translational modifications. These proteoforms can provide information about erythropoietic activity, myeloid activation, platelet production, coagulation, iron handling, tissue injury, and inflammatory signaling. Emerging mass spectrometry, affinity-based proteomics, and targeted immunoassays indicate that circulating proteoform patterns may distinguish transient physiological adaptation from persistent or pathological marrow stress. Their clinical value will depend on analytical standardization, longitudinal validation, control of preanalytical variation, and integration with hematological and clinical data. This review summarizes the biological basis, disease burden, risk factors, clinical manifestations, diagnostic applications, management implications, recent advances, and guideline considerations relevant to plasma proteoforms as biomarkers of hematopoietic stress.

Introduction

Hematopoiesis is continuously adjusted to maintain oxygen delivery, immune competence, hemostasis, and tissue repair. Under steady-state conditions, hematopoietic stem and progenitor cells generate mature blood cells according to tightly regulated interactions among bone marrow niches, cytokines, growth factors, metabolic signals, and peripheral tissue demands. Stress hematopoiesis occurs when these demands increase or when marrow function is impaired. It may be adaptive, as in acute blood loss or infection, or maladaptive, as in marrow failure, ineffective erythropoiesis, clonal hematopoiesis, inflammatory disease, or treatment-related toxicity.

Plasma contains proteins released from hematopoietic cells, stromal compartments, endothelial surfaces, liver, kidney, and injured tissues. A single protein may exist as multiple proteoforms with different molecular masses, charges, conformations, half-lives, receptor affinities, and biological activities. Measuring total protein concentration alone can therefore obscure clinically meaningful changes. For example, altered glycosylation of acute-phase proteins, cleavage of coagulation factors, oxidation of carrier proteins, or modified cytokine forms may reflect biological stress before conventional cell-count abnormalities become pronounced. Proteoform analysis seeks to preserve this molecular resolution and may support earlier recognition of pathophysiological transitions.

Epidemiology / Disease Burden

Hematopoietic stress is common across medical practice because it accompanies infection, cancer, chronic kidney disease, autoimmune disorders, liver disease, nutritional deficiencies, critical illness, pregnancy, major surgery, and exposure to chemotherapy or radiation. Anemia alone affects a substantial proportion of the global population, while thrombocytopenia and leukocyte abnormalities are frequent reasons for hospital evaluation and treatment modification. In critical care, systemic inflammation, endothelial dysfunction, renal impairment, and repeated phlebotomy may produce rapidly changing hematological profiles. In oncology, marrow infiltration, inflammatory suppression, cytotoxic therapy, and clonal evolution frequently coexist.

The burden is not limited to abnormal laboratory results. Hematopoietic stress can increase transfusion requirements, infection risk, bleeding, thromboembolic events, treatment interruptions, hospitalization, and mortality. Current biomarkers often identify established dysfunction rather than the earliest molecular response. Proteoform signatures could improve risk stratification by identifying patients whose marrow reserve is declining despite apparently stable cell counts. Population-level implementation, however, requires reference intervals that account for age, sex, ancestry, pregnancy, renal function, inflammation, medication exposure, and chronic disease.

Pathophysiology

Stress hematopoiesis is coordinated through erythropoietin, thrombopoietin, granulocyte colony-stimulating factor, stem cell factor, interleukins, interferons, tumor necrosis factor, transforming growth factor beta, and hypoxia-inducible signaling. Reduced oxygen delivery stimulates renal erythropoietin production and erythroid expansion, whereas infection and tissue injury activate emergency myelopoiesis. Inflammatory cytokines can simultaneously increase leukocyte output and suppress erythroid maturation through hepcidin induction, iron sequestration, altered progenitor survival, and impaired erythropoietin responsiveness.

Plasma proteoforms may reflect each stage of this response. Proteolytic fragments of extracellular matrix proteins can indicate marrow remodeling or endothelial injury. Modified transferrin, ferritin-related proteins, hemopexin, and hepcidin-associated molecules may signal altered iron trafficking. Proteoforms of complement components, acute-phase reactants, immunoglobulins, and coagulation proteins can reveal inflammatory and thrombo-inflammatory activation. Changes in platelet-derived proteins and megakaryocyte-associated factors may correspond to accelerated platelet production or peripheral consumption. In clonal hematopoiesis and myeloid neoplasia, abnormal secretion, mutation-dependent protein structure, and altered proteolysis may generate signatures distinguishable from reactive stress.

The biological interpretation must remain cautious. A plasma proteoform is not necessarily produced by a hematopoietic cell, and many markers are influenced by hepatic synthesis, kidney clearance, vascular permeability, and systemic inflammation. Mechanistic attribution therefore requires correlation with bone marrow findings, cell-free nucleic acids, cellular phenotyping, and longitudinal clinical assessment.

Risk Factors

Important risk factors include acute or chronic blood loss, iron, vitamin B12, or folate deficiency, chronic kidney disease, infection, autoimmune inflammation, malignancy, marrow infiltration, myelodysplastic syndromes, myeloproliferative neoplasms, chemotherapy, radiotherapy, marrow-toxic medications, alcohol exposure, severe nutritional compromise, and inherited marrow-failure syndromes. Older age increases the prevalence of clonal hematopoiesis and reduces hematopoietic reserve. Critical illness adds hypoxia, coagulation activation, organ dysfunction, and inflammatory signaling. Pregnancy, high-altitude exposure, major surgery, and endurance exercise may produce physiological stress patterns that overlap with disease-associated signatures.

Clinical Features

Clinical manifestations depend on the affected lineage and the speed of change. Erythroid stress may present with fatigue, exertional dyspnea, dizziness, tachycardia, or impaired cognitive performance. Neutrophil impairment increases susceptibility to bacterial and fungal infection, while excessive or dysregulated myelopoiesis may accompany fever and systemic inflammation. Platelet stress can produce petechiae, mucosal bleeding, bruising, or, in selected inflammatory and clonal disorders, thrombosis. Patients with multilineage dysfunction may have constitutional symptoms, recurrent infections, bleeding, weight loss, splenomegaly, or unexplained inflammatory findings.

Proteoform abnormalities are generally not clinically visible in isolation. Their value lies in contextualizing symptoms and routine results. A molecular pattern suggesting erythropoietic strain may support evaluation of occult blood loss or iron restriction, whereas a pattern associated with myeloid activation may encourage closer surveillance for infection, inflammatory disease, medication toxicity, or clonal marrow pathology.

Diagnosis

Initial assessment should include a complete blood count with indices and differential, peripheral blood smear, reticulocyte count, iron studies, renal and hepatic function, vitamin assays when indicated, inflammatory markers, hemolysis testing, and medication review. The clinical setting determines whether testing for infection, autoimmune disease, occult bleeding, malignancy, or nutritional deficiency is appropriate. Bone marrow examination remains essential when unexplained cytopenias, blasts, dysplasia, persistent abnormalities, or suspected marrow neoplasia are present.

Proteoform investigation can use top-down mass spectrometry, middle-down workflows, high-resolution liquid chromatography, capillary electrophoresis, immunoaffinity enrichment, and targeted assays for selected modified proteins. Analytical priorities include accurate molecular separation, preservation of labile modifications, internal standards, batch controls, and strict handling of collection tubes, processing time, temperature, and freeze-thaw cycles. Candidate panels should be tested against well-characterized disease groups and healthy controls, then validated prospectively for diagnostic discrimination, prognostic value, and clinical utility. Proteoform results should complement rather than replace blood counts, morphology, molecular testing, and specialist judgment.

Treatment & Management

Management is directed at the underlying cause and the clinically significant consequence. Iron, vitamin B12, or folate deficiency requires replacement and evaluation for the source of deficiency. Bleeding should be controlled, renal anemia addressed according to established nephrology practice, and infection treated promptly. When inflammation suppresses erythropoiesis, control of the inflammatory disorder may restore hematopoietic function. Transfusion decisions should consider symptoms, hemodynamic status, comorbid cardiovascular disease, active bleeding, and institutional protocols rather than proteoform values alone.

Growth factors, thrombopoietin receptor agonists, immunosuppressive therapy, targeted anticancer treatment, or hematopoietic stem-cell transplantation may be appropriate for selected disorders under specialist supervision. Proteoform patterns could eventually support treatment selection by identifying residual marrow reserve, early toxicity, impending relapse, or response to anti-inflammatory and hematopoietic therapies. At present, no proteoform measurement should independently trigger treatment without clinical and laboratory corroboration.

Recent Advances / Emerging Therapies

Recent advances include ultra-high-resolution mass spectrometry, data-independent acquisition, single-cell multi-omics, protein structural analysis, and machine-learning models that integrate proteoforms with blood counts, genomic alterations, and clinical outcomes. Longitudinal sampling is particularly important because stress responses are dynamic and may be more informative as trajectories than as isolated measurements. New methods are also improving the detection of low-abundance cytokine forms, glycoforms, proteolytic fragments, and protein complexes that were previously obscured by abundant plasma proteins.

Emerging therapeutic research includes agents that modulate hepcidin and iron availability, hypoxia-inducible factor signaling, inflammatory cytokine pathways, cellular senescence, and clonal hematopoiesis. In oncology, proteomic monitoring may be paired with minimal residual disease testing to identify relapse or treatment resistance. Major challenges include interlaboratory reproducibility, incomplete annotation of proteoform databases, uncertain biological specificity, high testing costs, and the need to demonstrate that biomarker-guided decisions improve patient outcomes.

Guideline Recommendations

Current clinical guidelines for anemia, neutropenia, thrombocytopenia, transfusion, chronic kidney disease, and hematological malignancy emphasize history, examination, serial blood counts, peripheral smear review, targeted biochemical testing, and appropriate marrow or molecular evaluation. These standards remain the foundation of care. A proteoform assay should be considered investigational unless it has undergone regulatory review and has validated performance for a defined clinical question.

For responsible incorporation into practice, clinicians and laboratories should use standardized specimen collection, document recent transfusion and medication exposure, interpret results with demographic and organ-function context, and avoid treating an isolated molecular abnormality. Multidisciplinary review is advisable when results suggest clonal disease, severe marrow failure, or unexplained multilineage stress. Professional societies should establish common nomenclature, analytical quality requirements, reporting standards, reference populations, and evidence thresholds for clinical adoption.

Conclusion

Plasma proteoforms provide a potentially sensitive molecular window into hematopoietic stress, linking marrow activity with inflammation, iron metabolism, coagulation, endothelial injury, and systemic disease. Their greatest future value may lie in detecting early dysfunction, separating adaptive from pathological responses, refining prognosis, and monitoring treatment in a longitudinal manner. Translation from discovery research to routine care requires rigorous analytical validation, mechanistic confirmation, standardized reporting, and prospective demonstration of improved clinical outcomes. Until those requirements are met, proteoform data should be interpreted as complementary evidence within a comprehensive hematological assessment rather than as a standalone diagnostic endpoint.